Future Outlook of the Cutaneous Squamous Cell Carcinoma (CSCC) Market: Growth, Trends, and Emerging Opportunities Explored
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the cutaneous squamous cell carcinoma (cscc) market size evolved in recent years?
In past years, the market size of cutaneous squamous cell carcinoma (cSCC) has experienced robust growth. It is projected to expand from $7.45 billion in 2024 to $7.90 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.1%. The significant growth observed during the historic period may be due to the increasing incidence of non-melanoma skin cancers, larger aging population, augmented exposure to ultraviolet radiation, enhancements in healthcare infrastructure, and a rise in the implementation of immunotherapy in the field of oncology.
What are the predictions for the cutaneous squamous cell carcinoma (cscc) market size in the coming years?
The market size for cutaneous squamous cell carcinoma (cSCC) is anticipated to observe substantial growth in the coming years, increasing to $9.90 billion by 2029 with a 5.8% compound annual growth rate (CAGR). Factors driving this forecasted growth include the rising availability of specific treatments, increased awareness regarding skin cancer prevention, growth in medical tourism concerning cancer therapies, escalated preference for minimally invasive surgeries, and supportive government measures for cancer care. Key trends predicted for the forecast period involve progress in dermatology diagnostics, advancements in radiotherapy techniques, integration of technology in dermatology, immunotherapy treatment innovations, and improved photodynamic therapy techniques.
Get your cutaneous squamous cell carcinoma (cscc) market report here!
What key factors are fueling the growth of the cutaneous squamous cell carcinoma (cscc) market?
The increase in skin cancer awareness is expected to drive the expansion of the cutaneous squamous cell carcinoma (cSCC) market. Skin cancer originates from the abnormal proliferation of skin cells, often resulting from excessive UV radiation, and can vary from harmless to life-threatening. The rising consciousness about skin cancer can be attributed to enhanced public health campaigns, better access to information, and an increasing emphasis on early detection and prevention, which generates a higher demand for diagnostic and treatment options. Cutaneous squamous cell carcinoma (cSCC) contributes to the improvement of skin cancer treatment by enabling specific therapies, improving diagnostic procedures, and enhancing patient outcomes, hence promoting efficient disease management. For example, in January 2024, the American Cancer Society, a US-based non-profit organization committed to fighting cancer, reported 104,930 skin cancer cases in 2023, a 3.2% increase from the 108,270 cases reported in 2022. Therefore, the escalating awareness about skin cancer is anticipated to stimulate growth in the cutaneous squamous cell carcinoma (cSCC) market.
How is the global cutaneous squamous cell carcinoma (cscc) market divided into key segments?
The cutaneous squamous cell carcinoma (CSCC) market covered in this report is segmented –
1) By Treatment: Surgical Treatment, Non-Surgical Treatment
2) By Diagnosis: Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Biopsy
3) By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Other Applications
Subsegments:
1) By Surgical Treatment: Excisional Surgery, Mohs Micrographic Surgery, Curettage And Electrodessication
2) By Non-Surgical Treatment: Radiation Therapy, Cryotherapy, Photodynamic Therapy, Topical Therapies, Systemic Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21163&type=smp
Who are the key firms paving the way for growth in the cutaneous squamous cell carcinoma (cscc) market?
Major companies operating in the cutaneous squamous cell carcinoma (CSCC) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, 3M Company, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Hikma Pharmaceuticals plc, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., CureVac N.V., Vidac Pharma Inc.
How are evolving market trends shaping cutaneous squamous cell carcinoma (cscc) Strategies?
Significant players in the cutaneous squamous cell carcinoma (cSCC) market are concentrating on advancements in immuno-oncology treatments including the PD-L1 inhibitors and targeted therapies, with the aim of enhancing patients’ results and providing efficient methods for handling advanced skin cancer. PD-L1, alternatively known as programmed death-ligand 1, is a protein that lowers the body’s immune response by binding to PD-1 receptors on T-cells, thereby assisting cancer cells to avoid detection by the immune system. For instance, Checkpoint Therapeutics Inc., a biotech company based in the US, got the approval from FDA for their product Unloxcyt (cosibelimab-ipdl) in December 2024. This innovation stands out due to its capacity to impede PD-L1, thereby boosting the immune system’s potency in combating cancer and in parallel, providing a safer and more efficient treatment option. Furthermore, it combines dual mechanisms of action, offering a hopeful approach for dealing with advanced cutaneous squamous cell carcinoma (cSCC). The approval was granted based on the results derived from the CK-301-101 trial, which showed significant objective response rates and sustained responses in patients grappling with advanced cSCC.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21163
What regions are contributing significantly to the growth of the cutaneous squamous cell carcinoma (cscc) market?
North America was the largest region in the cutaneous squamous cell carcinoma (CSCC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cutaneous squamous cell carcinoma (CSCC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Chromatin immunoprecipitation (ChIP) Sequencing Global Market Report 2025
Autoimmune Disease Diagnosis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report
Cyclic Heavy Menstrual Bleeding Global Market Report 2025
https://thebusinessresearchcompany.com/report/cyclic-heavy-menstrual-bleeding-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
